Novartis, the Swiss pharmaceutical group, is stepping up the case for use of its experimental pandemic flu vaccine even ahead of a new virus mutation that could trigger a future lethal outbreak in humans. 

Jörg Reinhardt, head of vaccines and diagnostics, said the company would publish scientific data showing that its H5 vaccine stimulates rapid protection with a second booster jab against pandemic flu strains for at least seven years.